NCT05462639
Introducing a clinical trial for people with relapsed/refractory multiple myeloma who have exhausted all other treatment options
The MagnetisMM studies are researching if the study medicine, elranatamab, can be both safe and effective in people with multiple myeloma. This “expanded access” trial is intended to provide access to elranatamab for people with relapsed/refractory multiple myeloma (RRMM) whose cancer has not responded to at least one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 antibody, until it becomes commercially available.
If you have RRMM and don’t have access to other treatment options, this trial may be an option for you
Who may participate
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
You will be contacted every 3 months to check your health status
Some studies require the study team to stay in contact with the participant for a period of time after the participant completes the main part of the study. This long-term follow up is to collect additional information on the study drug over time.
About the study medicine
This trial is intended to provide access to the study medicine, elranatamab, for people who have exhausted all other treatment options for multiple myeloma. The study medicine is a type of treatment called a bi-specific antibody and it will be given to all participants as a shot under the skin (called a subcutaneous injection).
The study medicine is thought to work by connecting T-cells (a type of cell in the immune system) to myeloma cells (cancer cells), potentially activating the immune cells to kill the cancer cells.
About the study medicine

Potential benefits and risks of taking part in the MagnetisMM-17 trial
By taking part in the MagnetisMM-17 trial, participants who do not have access to other comparable/alternative therapy will be able to access elranatamab, before it becomes commercially available.
Over the course of the trial, a participant’s health may get better, get worse, or stay the same. People who are considering taking part in the trial will be given a complete list of risks and possible discomforts before agreeing to participate. As with any medication, there may be a reaction to the study medicine.
Potential benefits and risks of taking part in the MagnetisMM-17 trial
